Equity · Healthcare
AMLX
NASDAQAmylyx Pharmaceuticals (AMLX)
The line runs 38 USD on 24 August through 26.03 USD on 20 November, on a scale from 25 to 40. Days the market did not trade hold the previous close, flat.
- Market cap
- 3.3B USD
- Revenue, year to Dec 2025
- 0 USD
- EPS, diluted, year to Dec 2025
- −1.53 USD
- 52-week range
- 11 USD – 39.67 USD
- Avg volume
- 86.4K
as of Nov 20, 2026
Have Amylyx Pharmaceuticals (AMLX) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Amylyx Pharmaceuticals insiders reported 10 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 21 May 2026.
Form 4, 90 days to 22 Nov 2026, newest reported trade 10 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 10 Nov 2026 | FRATES JAMES MChief Financial Officer | Sell | 20,000 | 611K USD |
| 09 Nov 2026 | Cohen Joshua BCo-Chief Executive Officer | Sell | 100,000 | 3.0M USD |
| 09 Nov 2026 | Klee Justin B.Co-Chief Executive Officer | Sell | 100,000 | 3.0M USD |
| 09 Nov 2026 | FRATES JAMES MChief Financial Officer | Sell | 20,000 | 597K USD |
| 05 Oct 2026 | MILNE GEORGE M JRDirector | Sell | 30,000 | 831K USD |
| 10 Sep 2026 | Bedrosian Camille LChief Medical Officer | Sell | 10,028 | 325K USD |
| 10 Sep 2026 | FRATES JAMES MChief Financial Officer | Sell | 10,810 | 350K USD |
| 10 Sep 2026 | Mazzariello GinaChief Legal Officer | Sell | 9,536 | 310K USD |
| 10 Sep 2026 | Cohen Joshua BCo-Chief Executive Officer | Sell | 30,464 | 981K USD |
| 10 Sep 2026 | Klee Justin B.Co-Chief Executive Officer | Sell | 30,464 | 980K USD |
| Sold | 10 open-market sales | 361,302 | $10.95M |
3 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 10 Nov 2026 | FRATES JAMES MChief Financial Officer | Option exercise | 20,000 | 138K USD |
| 09 Nov 2026 | FRATES JAMES MChief Financial Officer | Option exercise | 20,000 | 138K USD |
| 31 Aug 2026 | Firestone KarenDirector | Option exercise | 50,000 | 170K USD |
Which funds hold Amylyx Pharmaceuticals (AMLX)?
8 of the 45 institutional funds we track reported a Amylyx Pharmaceuticals position for the quarter ended 30 Sep 2026 — a combined 79.7M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Two Sigma Investments | Held (±25%) | 669,838 | 19.5M USD | +12.9% |
| D. E. Shaw & Co. | Added | 516,170 | 15.0M USD | +196.2% |
| Citadel Advisors | Added | 488,571 | 14.2M USD | +173.4% |
| Point72 Asset Management | New position | 388,699 | 11.3M USD | |
| Marshall Wace | New position | 377,026 | 11.0M USD | |
| Millennium Management | New position | 191,689 | 5.6M USD | |
| Renaissance Technologies | New position | 72,935 | 2.1M USD | |
| AQR Capital Management | Added | 35,281 | 1.0M USD | +69.5% |
| Balyasny Asset Management | Exited | |||
| Tudor Investment Corp | Exited |
Have members of Congress traded Amylyx Pharmaceuticals (AMLX)?
The most recent congressional trade disclosed in Amylyx Pharmaceuticals is a purchase by Sara Jacobs (house, CA), dated 12 Oct 2022.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 12 Oct 2022 | Sara Jacobshouse · Democrat–CA | Purchase | 1K USD–15K USD | 35 days |
What has been filed or recorded for Amylyx Pharmaceuticals (AMLX)?
The filings we hold for Amylyx Pharmaceuticals, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 22 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 22 Oct 2026 | Fails to deliver | Shares failed to deliver | 200,000 shares | 5.8M USD notional · 0.156% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.38 USD | |
| 30 Sep 2026 | Financials | Total assets | 786.8M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 753.7M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.39 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.37 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −1.53 USD | |
| 31 Dec 2025 | Financials | Revenue | 0 USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −144.7M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −1.53 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.37 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.46 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.42 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −4.43 USD |
What do people ask about Amylyx Pharmaceuticals (AMLX)?
What did Amylyx Pharmaceuticals shares close at?26.03
Amylyx Pharmaceuticals closed at 26.03 USD on 20 Nov 2026, down 0.53% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Amylyx Pharmaceuticals’ market cap?3.3B
Amylyx Pharmaceuticals is worth 3.3B USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Amylyx Pharmaceuticals’ revenue?0
Amylyx Pharmaceuticals reported revenue of 0 USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Amylyx Pharmaceuticals insiders bought or sold shares recently?10 sales
In the 90 days to 22 Nov 2026, Amylyx Pharmaceuticals insiders reported 10 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 21 May 2026. A further 3 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Amylyx Pharmaceuticals?8 of 45
8 of the 45 funds we track reported a Amylyx Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, D. E. Shaw & Co. and Citadel Advisors. See Funds
Have members of Congress traded Amylyx Pharmaceuticals?1 trade
Yes. 1 trade in Amylyx Pharmaceuticals appears in the congressional disclosures we hold: a purchase by Sara Jacobs (House, CA) dated 12 Oct 2022, filed 16 Nov 2022. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Amylyx Pharmaceuticals last report earnings?−0.38
Amylyx Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.38 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Sara Jacobs: Kristie Baxter, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words